Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNFISH: Risdiplam in Type 2 and 3 SMA
NCT02908685Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of risdiplam in spinal muscular atrophy type 2 (SMA2) and Spinal muscular atrophy type 3 (SMA3) (6 arms), sponsored by Roche. Primary endpoints: Selected Part 2 Dose of Risdiplam at 4 weeks and Motor Function Measure 32 Total Score at 12 months. Started Oct 2016; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy type 2 (SMA2)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on NCT02908685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908685.